RhumbLine Advisers’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-196,612
| Closed | -$7.73M | – | 4427 |
|
|
2023
Q2 | $7.73M | Buy |
196,612
+8,734
| +5% | +$308K | 0.01% | 1141 |
|
|
2023
Q1 | $4.57M | Buy |
187,878
+6,083
| +3% | +$133K | 0.01% | 1379 |
|
|
2022
Q4 | $3.89M | Buy |
181,795
+25,848
| +17% | +$552K | 0.01% | 1419 |
|
|
2022
Q3 | $2.8M | Buy |
155,947
+14,120
| +10% | +$185K | ﹤0.01% | 1587 |
|
|
2022
Q2 | $1.36M | Sell |
141,827
-3,913
| -3% | -$49.1K | ﹤0.01% | 1971 |
|
|
2022
Q1 | $2.45M | Buy |
145,740
+2,567
| +2% | +$37.9K | ﹤0.01% | 1707 |
|
|
2021
Q4 | $2.39M | Buy |
143,173
+15,852
| +12% | +$260K | ﹤0.01% | 1777 |
|
|
2021
Q3 | $2.07M | Buy |
127,321
+15,764
| +14% | +$172K | ﹤0.01% | 1898 |
|
|
2021
Q2 | $704K | Sell |
111,557
-4,692
| -4% | -$30.3K | ﹤0.01% | 2409 |
|
|
2021
Q1 | $718K | Sell |
116,249
-7,250
| -6% | -$44K | ﹤0.01% | 2329 |
|
|
2020
Q4 | $853K | Buy |
123,499
+32,968
| +36% | +$211K | ﹤0.01% | 2212 |
|
|
2020
Q3 | $511K | Buy |
90,531
+27,352
| +43% | +$130K | ﹤0.01% | 2282 |
|
|
2020
Q2 | $322K | Buy |
+63,179
| New | +$263K | ﹤0.01% | 2543 |
|
|
2017
Q2 | – | Sell |
-36,440
| Closed | -$133K | – | 2971 |
|
|
2017
Q1 | $133K | Buy |
36,440
+1,277
| +4% | +$5.4K | ﹤0.01% | 2743 |
|
|
2016
Q4 | $170K | Buy |
35,163
+1,979
| +6% | +$58.7K | ﹤0.01% | 2711 |
|
|
2016
Q3 | $1.53M | Buy |
33,184
+3,072
| +10% | +$173K | ﹤0.01% | 1576 |
|
|
2016
Q2 | $1.54M | Buy |
30,112
+5,377
| +22% | +$267K | ﹤0.01% | 1535 |
|
|
2016
Q1 | $1.05M | Buy |
24,735
+240
| +1% | +$12.2K | ﹤0.01% | 1759 |
|
|
2015
Q4 | $1.92M | Buy |
24,495
+3,080
| +14% | +$178K | 0.01% | 1381 |
|
|
2015
Q3 | $868K | Buy |
21,415
+541
| +3% | +$28.7K | ﹤0.01% | 1860 |
|
|
2015
Q2 | $1.09M | Buy |
20,874
+7,735
| +59% | +$385K | ﹤0.01% | 1808 |
|
|
2015
Q1 | $611K | Buy |
13,139
+2,245
| +21% | +$117K | ﹤0.01% | 2174 |
|
|
2014
Q4 | $489K | Sell |
10,894
-450
| -4% | -$18.9K | ﹤0.01% | 2291 |
|
|
2014
Q3 | $442K | Sell |
11,344
-750
| -6% | -$29.4K | ﹤0.01% | 2286 |
|
|
2014
Q2 | $512K | Buy |
+12,094
| New | +$444K | ﹤0.01% | 2256 |
|
RhumbLine Advisers's ISEE Position: Q3 2023 in Review
RhumbLine Advisers sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 196,612 shares — an estimated $7.73M sold.
RhumbLine Advisers first reported a position in ISEE in Q2 2014 and held it in 25 quarters. The position peaked at $7.73M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- RhumbLine Advisers reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- RhumbLine Advisers sold 196,612 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $7.73M.
- RhumbLine Advisers first reported a position in IVERIC bio, Inc. Common Stock in Q2 2014 and held it in 25 quarters.
- RhumbLine Advisers's IVERIC bio, Inc. Common Stock position peaked at $7.73M in Q2 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.